These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 32248831)

  • 81. Decreased outlet angle of the superior cerebellar artery as indicator for dolichoectasia in late onset Pompe disease.
    Hensel O; Schneider I; Wieprecht M; Kraya T; Zierz S
    Orphanet J Rare Dis; 2018 Apr; 13(1):57. PubMed ID: 29653542
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Diagnostic tools in late onset Pompe disease (LOPD).
    Musumeci O; Toscano A
    Ann Transl Med; 2019 Jul; 7(13):286. PubMed ID: 31392198
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Newborn screening for Pompe disease in Italy: Long-term results and future challenges.
    Gragnaniello V; Pijnappel PWWM; Burlina AP; In 't Groen SLM; Gueraldi D; Cazzorla C; Maines E; Polo G; Salviati L; Di Salvo G; Burlina AB
    Mol Genet Metab Rep; 2022 Dec; 33():100929. PubMed ID: 36310651
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Targeted gene panel screening is an effective tool to identify undiagnosed late onset Pompe disease.
    Savarese M; Torella A; Musumeci O; Angelini C; Astrea G; Bello L; Bruno C; Comi GP; Di Fruscio G; Piluso G; Di Iorio G; Ergoli M; Esposito G; Fanin M; Farina O; Fiorillo C; Garofalo A; Giugliano T; Magri F; Minetti C; Moggio M; Passamano L; Pegoraro E; Picillo E; Sampaolo S; Santorelli FM; Semplicini C; Udd B; Toscano A; Politano L; Nigro V
    Neuromuscul Disord; 2018 Jul; 28(7):586-591. PubMed ID: 29880332
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Transcriptomic characterization of clinical skeletal muscle biopsy from late-onset Pompe patients.
    Kinton S; Dufault MR; Zhang M; George K
    Mol Genet Metab; 2023 Mar; 138(3):107526. PubMed ID: 36774918
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory efficacy of the novel enzyme replacement therapy avalglucosidase alfa (neoGAA) in treatment-naïve and alglucosidase alfa-treated patients with late-onset Pompe disease: A phase 1, open-label, multicenter, multinational, ascending dose study.
    Pena LDM; Barohn RJ; Byrne BJ; Desnuelle C; Goker-Alpan O; Ladha S; Laforêt P; Mengel KE; Pestronk A; Pouget J; Schoser B; Straub V; Trivedi J; Van Damme P; Vissing J; Young P; Kacena K; Shafi R; Thurberg BL; Culm-Merdek K; van der Ploeg AT;
    Neuromuscul Disord; 2019 Mar; 29(3):167-186. PubMed ID: 30770310
    [TBL] [Abstract][Full Text] [Related]  

  • 87. [Late onset Pompe disease: an analysis of 19 patients from Mexico].
    Sánchez-Sánchez LM; Martinez-Montoya V; Sandoval-Pacheco R; Torres-Octavo B; Anaya-Castro DM; Padilla-de la Torre O; Arellano-Valdez CA; Ávila-Rejón CA; Aguilar-Juárez PA; Espino-Pluma M; González-Santillanes Cruz A; Kazakova E; Martinez-Segovia RI; Olmos-Morfin D; Radillo-Díaz PF; Solís-Sánchez I; Vázquez Del Mercado-Espinosa M; Villarroel-Cortés CE; Velarde-Félix JS
    Rev Neurol; 2022 Sep; 75(5):103-108. PubMed ID: 35880963
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Muscle Proteomic Profile before and after Enzyme Replacement Therapy in Late-Onset Pompe Disease.
    Moriggi M; Capitanio D; Torretta E; Barbacini P; Bragato C; Sartori P; Moggio M; Maggi L; Mora M; Gelfi C
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33799647
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Improvement of bone mineral density after enzyme replacement therapy in Chinese late-onset Pompe disease patients.
    Sheng B; Chu YP; Wong WT; Yau EKC; Chen SPL; Luk WH
    BMC Res Notes; 2017 Jul; 10(1):351. PubMed ID: 28754168
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Prospective exploratory muscle biopsy, imaging, and functional assessment in patients with late-onset Pompe disease treated with alglucosidase alfa: The EMBASSY Study.
    van der Ploeg A; Carlier PG; Carlier RY; Kissel JT; Schoser B; Wenninger S; Pestronk A; Barohn RJ; Dimachkie MM; Goker-Alpan O; Mozaffar T; Pena LD; Simmons Z; Straub V; Guglieri M; Young P; Boentert M; Baudin PY; Wens S; Shafi R; Bjartmar C; Thurberg BL
    Mol Genet Metab; 2016 Sep; 119(1-2):115-23. PubMed ID: 27473031
    [TBL] [Abstract][Full Text] [Related]  

  • 91. [The long-term follow-up of enzyme replacement treatment in late onset Pompe disease].
    Molnár MJ; Borsos B; Várdi KV; Grosz Z; Sebők Á; Dézsi L; Almássy Z; Kerényi L; Jobbágy Z; Jávor L; Bidló J
    Ideggyogy Sz; 2020 May; 73(05-06):151-159. PubMed ID: 32579304
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Urodynamic and clinical studies in patients with late-onset Pompe disease and lower urinary tract symptoms.
    Kuchenbecker KS; Kirschner-Hermanns R; Kornblum C; Jaekel A; Anding R; Kohler A
    Neurourol Urodyn; 2020 Jun; 39(5):1437-1446. PubMed ID: 32343026
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Intracranial vasculopathy: an important organ damage in young adult patients with late-onset Pompe disease.
    Zhao Y; Yu X; Li D; He J; Li Y; Zhang B; Zhang N; Wang Q; Yan C
    Orphanet J Rare Dis; 2024 Jul; 19(1):267. PubMed ID: 39010129
    [TBL] [Abstract][Full Text] [Related]  

  • 94. [Analysis of lysosomal enzyme activity and genetic variants in a child with late-onset Pompe disease].
    He T; Jiang J; Xiong Y; Yu D; Zhang X
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2023 Jun; 40(6):711-717. PubMed ID: 37212008
    [TBL] [Abstract][Full Text] [Related]  

  • 95. High-risk screening of late-onset Pompe disease: A different early portrait in China.
    Jiao K; Dong J; Luo S; Yu L; Ke Q; Wang Z; Luan X; Zhang X; Guo J; Chen Y; Li X; Tan S; Qian F; Jiang J; Yu X; Yue D; Liu C; Luo L; Li J; Qu Y; Chen L; Tu J; Sun C; Yan C; Song J; Xi J; Lin J; Lu J; Zhao C; Zhu W; Fang Q
    Front Neurol; 2022; 13():965207. PubMed ID: 36237614
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Muscle imaging data in late-onset Pompe disease reveal a correlation between the pre-existing degree of lipomatous muscle alterations and the efficacy of long-term enzyme replacement therapy.
    Gruhn KM; Heyer CM; Güttsches AK; Rehmann R; Nicolas V; Schmidt-Wilcke T; Tegenthoff M; Vorgerd M; Kley RA
    Mol Genet Metab Rep; 2015 Jun; 3():58-64. PubMed ID: 26937398
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Evaluating avalglucosidase alfa for the management of late-onset Pompe disease.
    Angelini C
    Expert Rev Neurother; 2024 Mar; 24(3):259-266. PubMed ID: 38261315
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Restrictive Arteriopathy in Late-Onset Pompe Disease: Case Report and Review of the Literature.
    Malhotra K; Carrington DC; Liebeskind DS
    J Stroke Cerebrovasc Dis; 2017 Aug; 26(8):e172-e175. PubMed ID: 28647415
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Vacuolated PAS-positive lymphocytes as an hallmark of Pompe disease and other myopathies related to impaired autophagy.
    Pascarella A; Terracciano C; Farina O; Lombardi L; Esposito T; Napolitano F; Franzese G; Panella G; Tuccillo F; la Marca G; Bernardini S; Boffo S; Giordano A; Di Iorio G; Melone MAB; Sampaolo S
    J Cell Physiol; 2018 Aug; 233(8):5829-5837. PubMed ID: 29215735
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Rapid progressive course of later-onset Pompe disease in Chinese patients.
    Yang CC; Chien YH; Lee NC; Chiang SC; Lin SP; Kuo YT; Chen SS; Jong YJ; Hwu WL
    Mol Genet Metab; 2011 Nov; 104(3):284-8. PubMed ID: 21757382
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.